Details for New Drug Application (NDA): 020191
✉ Email this page to a colleague
The generic ingredient in ALOMIDE is lodoxamide tromethamine. Additional details are available on the lodoxamide tromethamine profile page.
Summary for 020191
| Tradename: | ALOMIDE |
| Applicant: | Novartis |
| Ingredient: | lodoxamide tromethamine |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | EQ 0.1% BASE | ||||
| Approval Date: | Sep 23, 1993 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 020191
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | ALOMIDE | lodoxamide tromethamine | SOLUTION/DROPS;OPHTHALMIC | 020191-001 | Sep 23, 1993 | 5,457,126 | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
